argenex SE $ARGX Position Boosted by Bessemer Group Inc.

Bessemer Group Inc. lifted its stake in shares of argenex SE (NASDAQ:ARGX) by 97,614.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 62,537 shares of the company’s stock after purchasing an additional 62,473 shares during the period. Bessemer Group Inc.’s holdings in argenex were worth $52,590,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of ARGX. AQR Capital Management LLC lifted its position in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares during the last quarter. NewEdge Advisors LLC lifted its position in shares of argenex by 5,962.5% during the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares during the last quarter. Focus Partners Wealth lifted its position in shares of argenex by 22.3% during the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Trading Down 2.8%

Shares of NASDAQ:ARGX opened at $799.32 on Friday. The firm’s 50 day moving average is $760.29 and its two-hundred day moving average is $816.75. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The firm has a market capitalization of $49.71 billion, a P/E ratio of 35.59, a PEG ratio of 1.31 and a beta of 0.46.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The company had revenue of $1.31 billion for the quarter. Analysts predict that argenex SE will post 25.08 EPS for the current year.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several research reports. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. HC Wainwright increased their price objective on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Oppenheimer dropped their price objective on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Citizens Jmp raised their price target on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, argenex has a consensus rating of “Moderate Buy” and a consensus price target of $1,017.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.